The Prognosis of Mitt Romney’s Cancer by David Samadi

Mitt Romney, a former presidential nominee, recently made it public that he has prostate cancer. Dr. David Samadi says that he underwent surgery for a tumor in his prostate area. By going public with this news means that Mitt might be planning to run for Senate position in Ohio. Dr. Thomas of California’s UC Irvine Hospital is the surgeon who performed the surgery. Older men of at least 65 years are more likely to get prostate cancer than younger men. Romney is 70 years old. Patients diagnosed with prostate cancer can opt for either surgical treatment or radiation.

Other Similar Cases in U.S. History

While Colin Powell was Secretary of State in 2003, he went to Walter Reed Army Medical Center for removal of his prostate gland. John Kerry also learned that he had prostate cancer while running for presidency in 2002. Luckily, both cases were treated successfully.

Reasons Why Surgery Is Considered Better than Radiation

Radiation exposure may put the men at risk of getting other forms of cancer like rectal or bladder cancer as a side effect of radiation

  • Men treated using radiation have a higher chance of dying from prostate cancer. They also have a higher chance of dying compared to those undergo surgery for the same
  • Men with localized cancer and who opt for surgery have a survival rate of 100%. When a man opts for radiation first and then changes to surgery, his chances of living more than 5 years becomes at most 29%

It is important that men with prostate cancer know more about a surgeon before they go ahead with the treatment. They should ask about the number of years he has been in the business and the number of successful cases he has dealt with. The patients should also ask about the probable side effects in terms of sex and urination. The more informed you are about a treatment procedure, the more prepared you will be for it.

More on David Samadi

Samadi is a 48 year old prostrate surgeon at the Lenox Hill Hopital. He has been successful in treating more than 7000 prostate cancer cases. David was born in the Middle East. He has lived in Europe and now lives in the United States. He has performed robotic surgery in many nations across the globe. All his cases have been successful. He also appears on Fox News on a weekly basis.

To know more visit @

Tempus is Helping to Fight Cancer Using Data-Enabled Precision Medicine

Many US Citizens every year develop some kind of cancer including children. Eric Lefkofsky, co-founder of Tempus, is leading the fight against this disease by using data enabled precision medicine. In 2014, approximately 14.5 million people in the United States were diagnosed as having cancer.

In the past, the healthcare industry was more concerned about electronic medical records (EMR) instead of treating cancer patients. Back when Eric Lefkofsky got involved in helping find a cure for cancer is when his wife was diagnosed with breast cancer. He discovered that there was a gapping hole in terms of data collection and digital technology in the following: click here.

Until Tempus came into existence, there was still a lot of work to be done with data collection and digital technology. Tempus has created a unique platform in analyzing patient’s clinical and molecular data. The company had come up with developing the analytics software; however, there was a lack of funding.

Another difficulty was how to access crucial information in regards to how data was stored cancer patients. Most of the time, the information was found in physicians’ notes, leaving it difficult to analyze the data needed. Tempus developed a software that has natural language processing and optical character recognition capabilities. Finally, the information could be transferred from physicians’ notes into structured data.

The molecular data, which is called genomic information is collected through human genomic sequencing. Compared to $100 million in 2003, now this software has gone down to $5000 and will continue to go down in price thanks to science and technology.

Tempus is leading the fight to finding cure for treating cancer by using genomic sequencing. Human genes hold the clue to finding a cure for different kinds of diseases, like cancer. The Tempus Company is using software allowing clinical information, regarding the patient, to be treated with molecular information through genomic sequencing.

There will come a time, in the future, thanks to the Tempus Company, doctors will be able to diagnose diseases more effectively, like cancer through data-enabled precision medicine. Then doctors will have more effective treatments that will work thanks to Eric Lefkofsky, co-founder of Tempus.

The Accomplishments Of Eric Lefkovsky

Eric Lefkovsky is a CEO and co-founder of the cancer-fighting technological company Tempus. Before starting Tempus in 2016, Lefkovsky had worked for various technological companies. He founded Groupon, which originally was called The Point, and helped the company raise $950 million by raising capital from different partners. In 2015, he stepped down as the company’s CEO but remained a Groupon Chairman. He soon began working on other projects such as Uptake, LLC which provides data to help drive industry results. From that idea, he began to visualize the need for physicians to use data to solve many of the problems associated with cancer treatments and he started Tempus.


Tempus is a health technology company that was designed to provide cancer specialists with data-driven treatment options. Through technology, physicians can get instant molecular analysis and genomic sequencing findings to make real life decisions for their cancer patients. They use past treatment data to determine the best patient care services they can provide at the present moment.

Eric Lefkofsky knew that by studying genomic data, new therapeutic strategies for stopping the spread of tumors and oncogenes can be designed and implemented. He understood that hospitals, bio-medical research facilities, and universities have all been using data to come up with solutions for the unpredictabilities of cancer cells. Mutations in cells lead to complex systems that require certain algorithms in order to stop its progress and regeneration over time. Sometimes the pace of treatments can be slow due to regulations, so having access to information on Tempus can allow health professionals to determine what has been effective and what has not been effective in cancer treatments.


Lefkofsky has been involved in philanthropic efforts. He began The Lefkofsky Family Foundation with his wife Liz in 2006. The charitable foundation operates to help advance research, start-ups, and programs whose goal is to improve community life. The goal of the foundation is to help provide a good education to all children, excel human rights initiatives, and discover new medical interventions. Children are the main focus of the foundation and it has provided funds to over 50 organizations. He and his wife have also joined The Giving Pledge, a campaign whose focus is to encourage generosity among wealthy people to help care for the less fortunate.


Community interest is something that Lefkofsky is involved with as well. He is on the Board of Directors at several Chicago-based companies including The Children’s Memorial Hospital, The Art Institute, The Trustee of Steppenwolf Theatre Company, The Museum of Science and Technology and World Business Chicago.


His innovative ideas have transformed health and technological industries and helped serve the needs of many people including individuals with cancer and children.

Read more about Lefkofsky here: